 WALTHAM, Mass., Aug. 02, 2021 GLOBE NEWSWIRE -- Minerva Neurosciences, Inc. Nasdaq: NERV, a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system CNS disorders, today reported key business updates and financial results for the quarter ended June 30, 2021. 